Gastroenterology or gastrology is the medical specialty concerned with digestive diseases. Traditionally, these are separated by anatomic or functional category. For example, disorders of the esophagus might be listed under "esophagus" and also included in a description of motility disorders (disorders of motor function.) Diseases of the liver fall under the branch of hepatology, which is traditionally classified under the umbrella of gastroenterology.

List of signs and symptoms of gastroenterological diseases:

• constipation
• diarrhea
• vomiting
• nausea
• abdominal pain

List of research fields in Gastroenterology:

• Neurogastroenterology
• Motility

More on [ Gastroenterology ]

All Gastroenterology Jobs

Permanent Gastroenterology Job in Williamson Kentucky with Appalachian Regional Healthcare
Williamson ARH Hospital BC/BE Gastroenterologist Williamson ARH Hospital is seeking a BC/BE Gastroenterologist to join its medical staff. Our 163-bed community hospital prides itself with a high
Permanent Gastroenterology Job in Laurinburg North Carolina with Scotland Memorial Hospital
GASTROENTEROLOGY OPPORTUNITY North Carolina Join 2 physicians in progressive, family-oriented community selected for the third time as 1 of 10 All America Cities in the nation. 1:3 call schedule.
Permanent Gastroenterology Job in NW PA Pennsylvania with BioPointe
Are you thinking about a practice change or newly out of training? Well, I would like to share with you a little bit about our opportunity for BC/BE Gastroenterologists here in Pennsylvania as we plan

FeedNavigator - Journals - Gastroenterology

Pseudomyxoma Peritonei Masquerading As Ascites Secondary to Alcoholic Cirrhosis.
Digestive Diseases and Sciences / Terkko Sat, 04 Jul 2009 16:48:40 +0300

Liver Abscesses, Pylephlebitis, and Appendicitis in an Adolescent Male.
Digestive Diseases and Sciences / Terkko Sat, 04 Jul 2009 16:48:40 +0300

Crohn's Colitis Complicated by Cytomegalovirus Infection.
Digestive Diseases and Sciences / Terkko Sat, 04 Jul 2009 16:48:40 +0300

A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity.
World Journal of Gastroenterology / Terkko Sat, 04 Jul 2009 15:58:37 +0300

An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.
World Journal of Gastroenterology / Terkko Sat, 04 Jul 2009 15:58:37 +0300

Molecular characteristics and stages of chronic hepatitis B virus infection.
World Journal of Gastroenterology / Terkko Sat, 04 Jul 2009 15:58:37 +0300


pubmed: 1542-3565

Reply: Persistent Nausea and Abdominal Pain in a Patient with Delayed Gastric Emptying: Shall We Think of Celiac Disease?
Friedenberg FK, Parkman HP Related Articles Reply: Persistent Nausea and Abdominal Pain in a Patient with Delayed Gastric Emptying: Shall We Think of Celiac Disease? Clin Gastroenterol Hepatol. 2009 Jun 26; Authors: Friedenberg FK, Parkman HP PMID: 19563914 [PubMed - as supplied by publisher]
Reply:
Ananthakrishnan AN, McGinley EL, Saeian K Related Articles Reply: Clin Gastroenterol Hepatol. 2009 Jun 26; Authors: Ananthakrishnan AN, McGinley EL, Saeian K PMID: 19563913 [PubMed - as supplied by publisher]

Nature Reviews Gastroenterology & Hepatology

The burdens of digestive diseases
Stephen B. HanauerAlthough this journal has an international readership, a recent publication (Everhart, J. E. US Department of Health and Human Services NIDDK National Institute of Diabetes and Digestive and Kidney Diseases [online], [2009]) provides an interesting reference point for the incidence, prevalence and
Liver: Simvastatin might be an effective therapy for portal hypertension in cirrhosis
Rachel Jones Liver: Simvastatin might be an effective therapy for portal hypertension in cirrhosis Nature Reviews Gastroenterology & Hepatology 6, 379 (2009). doi:10.1038/nrgastro.2009.96 Author: Rachel Jones
Hepatitis C: Angiotensin blockade—halting liver fibrosis
Susan J. Allison Hepatitis C: Angiotensin blockade—halting liver fibrosis Nature Reviews Gastroenterology & Hepatology 6, 380 (2009). doi:10.1038/nrgastro.2009.91 Author: Susan J. Allison

Inflammatory Bowel Diseases

Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model
Laurent Pouyet, Céline Roisin-Bouffay, Aurélie Clément, Virginie Millet, Stéphane Garcia, Lionel Chasson, Nathalie Issaly, Agathe Rostan, Paul Hofman, Philippe Naquet, Franck Galland Wed, 01 Jul 2009 17:29:00 -0000
Vanin-1 is an epithelial pantetheinase that provides cysteamine to tissue and regulates response to stress. Vanin-1 is expressed by enterocytes, and its absence limits intestinal epithelial cell production of proinflammatory signals. A link between chronic active inflammation and cancer is illustrated in patients with ulcerative colitis, who have an augmented risk of developing colorectal cancer. Indeed, sustained inflammation provides advantageous growth conditions to tumors. We examined whether epithelial cells affect tumorigenesis through vanin-1-dependent modulation of colonic inflammation.To vanin-1-/- mice, we applied the colitis-associated cancer (CAC) protocol, which combines injection of azoxymethane (AOM) with repeated administrations of dextran sodium sulfate (DSS). We numbered tumors and quantified macrophage infiltration and molecular markers of cell death and proliferation. We also tested DSS-induced colitis. We scored survival, tissue damages, proinflammatory cytokine production, and tissue regeneration. Finally, we explored activation pathways by biochemical analysis on purified colonic epithelial cells (CECs) and in situ immunofluorescence.Vanin-1-/- mice displayed a drastically reduced incidence of colorectal cancer in the CAC protocol and manifested mild clinical signs of DSS-induced colitis. The early impact of vanin-1 deficiency on tumor induction was directly correlated to the amount of inflammation and subsequent epithelial proliferation rather than cell death rate; all this was linked to the modulation of NF-[kappa]B pathway activation in CECs.These results emphasize the importance of the intestinal epithelium in the control of mucosal inflammation acting as a cofactor in carcinogenesis. This might lead to novel anti-inflammatory strategies useful in cancer therapy. Inflamm Bowel Dis 2009
Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis
Tsukasa Ishida, Masaru Yoshida, Makoto Arita, Yosuke Nishitani, Shin Nishiumi, Atsuhiro Masuda, Shigeto Mizuno, Tetsuya Takagawa, Yoshinori Morita, Hiromu Kutsumi, Hideto Inokuchi, Charles N. Serhan, Richard S. Blumberg, Takeshi Azuma Wed, 01 Jul 2009 17:29:00 -0000
Resolvin E1 (RvE1), an endogenous lipid mediator derived from eicosapentaenoic acid, has been identified in local inflammation during the healing stage. RvE1 reduces inflammation in several types of animal models including peritonitis and retinopathy and blocks human neutrophil transendothelial cell migration. The RvE1 receptor ChemR23 is expressed on myeloid cells such as macrophages and dendritic cells. The aim of this study was to determine whether RvE1 regulates colonic inflammation when the innate immune response of macrophages plays a key role in pathogenesis and tissue damage.The RvE1 receptor ChemR23 was expressed in mouse peritoneal macrophages as defined by flow cytometry. Peritoneal macrophages were pretreated with RvE1, followed by lipopolysaccharide stimulation, whereupon transcriptional levels of proinflammatory cytokines were analyzed.RvE1 treatment led to inhibition of proinflammatory cytokines including TNF-[alpha] and IL-12p40. In HEK293 cells, pretreatment with RvE1 inhibited TNF-[alpha]-induced nuclear translocation of NF-[kappa]B in a ChemR23-dependent manner. These results suggested that RvE1 could regulate proinflammatory responses of macrophages expressing ChemR23. Therefore, we investigated the beneficial effects of RvE1 in dextran sulfate sodium-induced colitis. RvE1 treatment led to amelioration of colonic inflammation.These results indicate that RvE1 suppresses proinflammatory responses of macrophages. RvE1 and its receptor may therefore be useful as therapeutic targets in the treatment of human inflammatory bowel disease and other inflammatory disorders. Inflamm Bowel Dis 2009
Quality of care in inflammatory bowel disease: A review and discussion
Michael D. Kappelman, Lena Palmer, Brendan M. Boyle, David T. Rubin Wed, 01 Jul 2009 17:29:00 -0000
The Institute of Medicine's publications To Err Is Human and Crossing the Quality Chasm publicized the widespread deficits in U.S. health care quality. Emerging studies continue to reveal deficits in the quality of adult and pediatric care, including subspecialty care. The inflammatory bowel diseases (IBD) Crohn's disease and ulcerative colitis require diligent, long-term management and attention to their impact on intestinal and extraintestinal organ systems. Although the quality of IBD care has not been prospectively or comprehensively evaluated in the United States, several small studies have demonstrated significant variation in care. As variation may indicate underuse, overuse, or misuse of medical services, such variation suggests a clear need for translating evidence-based practices into the actual practice and follow-up provided for patients. This article reviews the history, rationale, and methods of quality measurement and improvement and identifies the unique challenges in adapting these general strategies to the care of the inflammatory bowel diseases. Inflamm Bowel Dis 2009

Subscribe to Gastroenterology RSS feed